Industry: MRI contrast agents
Inlighta Biosciences’ patent-protected technology develops protein-based MRI contrast agents.
Existing MRI contrast agents are limited in their ability to support molecular imaging of liver tissues and liver tumors, which poses barriers to cancer diagnosis and treatment. The contrast agents developed by Inlighta offer higher contrast and more precise targeting in hard-to-image areas of the body, such as liver tissue.
Inlighta’s technology could benefit clinical diagnostics, which uses MRI contrast to diagnose tumors, heart conditions, muscular-skeletal problems and other disorders. Another relevant area is the molecular imaging market, today’s fastest-growing diagnostic field, which no MRI contrast agents are currently able to target.
Company website: Inlighta Biosciences